Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Ralf-Holger Voss"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/49ca0efa663f40a4864a6eaebe922b13
Autor:
Khadijeh Alishah, Matthias Birtel, Elham Masoumi, Leila Jafarzadeh, Hamid Reza Mirzaee, Jamshid Hadjati, Ralf-Holger Voss, Mustafa Diken, Sedighe Asad
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-21 (2021)
Abstract Background CAR T-cell therapy has been recently unveiled as one of the most promising cancer therapies in hematological malignancies. However, solid tumors mount a profound line of defense to escape immunosurveillance by CAR T-cells. Among t
Externí odkaz:
https://doaj.org/article/8769556c873e4b6a8c4b997f63fda4a0
Autor:
Markus Munder, Melanie Engelhardt, Diana Knies, Sergej Medenhoff, Guido Wabnitz, Claudia Luckner-Minden, Nadja Feldmeyer, Ralf-Holger Voss, Pascale Kropf, Ingrid Müller, Roland Conradi, Yvonne Samstag, Matthias Theobald, Anthony D Ho, Hartmut Goldschmidt, Michael Hundemer
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63521 (2013)
Tumor-growth is often associated with the expansion of myeloid derived suppressor cells that lead to local or systemic arginine depletion via the enzyme arginase. It is generally assumed that this arginine deficiency induces a global shut-down of T c
Externí odkaz:
https://doaj.org/article/430fcc64c0b54f14bdb91bc0692fa96e
Autor:
Shao-An Xue, Liquan Gao, Sharyn Thomas, Daniel P. Hart, John Zhao Xue, Roopinder Gillmore, Ralf-Holger Voss, Emma Morris, Hans J. Stauss
Publikováno v:
Haematologica, Vol 95, Iss 1 (2010)
Background The Wilms’ tumor antigen (WT1) is an attractive target for immunotherapy of leukemia. In the past, we isolated and characterized the specificity and function of a WT1-specific T-cell receptor. The goal of this translational study was to
Externí odkaz:
https://doaj.org/article/699338069e4547339921aed93d2bd478
Autor:
Matthias Birtel, Ralf-Holger Voss, Katharina Reinhard, Benjamin Rengstl, Yasmina Ouchan, Kristina Michel, Nina Hayduk, Bodo Tillmann, René Becker, Martin Suchan, Matthias Theobald, Petra Oehm, Özlem Türeci, Ugur Sahin
Publikováno v:
Cancer Research Communications. 2:827-841
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pair
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6194315ef54821c15f36097b135ec10
https://doi.org/10.1158/2767-9764.crc-21-0154
https://doi.org/10.1158/2767-9764.crc-21-0154
Autor:
Ugur Sahin, Özlem Türeci, Petra Oehm, Matthias Theobald, Martin Suchan, René Becker, Bodo Tillmann, Nina Hayduk, Kristina Michel, Yasmina Ouchan, Benjamin Rengstl, Katharina Reinhard, Ralf-Holger Voss, Matthias Birtel
Supplementary Data and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::381bcc291c56fb9800786f04933391af
https://doi.org/10.1158/2767-9764.22545446
https://doi.org/10.1158/2767-9764.22545446
Autor:
Ugur Sahin, Özlem Türeci, Petra Oehm, Matthias Theobald, Martin Suchan, René Becker, Bodo Tillmann, Nina Hayduk, Kristina Michel, Yasmina Ouchan, Benjamin Rengstl, Katharina Reinhard, Ralf-Holger Voss, Matthias Birtel
Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pair
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc213ba4971e2ef943dc981633019540
https://doi.org/10.1158/2767-9764.c.6550946.v1
https://doi.org/10.1158/2767-9764.c.6550946.v1
Autor:
Ralf-Holger Voss, Hans J. Stauss, Liquan Gao, Shao-An Xue, Laura Scolamiero, Emma C. Morris, Feng-Qin He, Bo Wang, Xiao-Xia Cheng, Virad Kisan, Yuan Chen, Ke-Ke Chen, Angelika Holler
Publikováno v:
Cell Mol Immunol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::438732057f2da12ebcd9029fcbbb87f3
https://pubmed.ncbi.nlm.nih.gov/32203185
https://pubmed.ncbi.nlm.nih.gov/32203185
Autor:
Sebastian Kreiter, Mathias Vormehr, Mustafa Diken, Christian Grunwitz, Matthias Birtel, Jutta Petschenka, Fulvia Vascotto, Lena M. Kranz, Ralf-Holger Voss, Lina Hilscher
Publikováno v:
Human Vaccines & Immunotherapeutics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f6960c871107e8fd9f9ac8fca7359c
https://doi.org/10.1080/21645515.2016.1206677
https://doi.org/10.1080/21645515.2016.1206677
Autor:
Hakim Echchannaoui, Ugur Sahin, Philippe Guillaume, Sebastian Klobuch, Simone Thomas, Matthias Birtel, Ralf-Holger Voss, Hans J. Stauss, Tana Omokoko, Matthias Theobald, Wolfgang Herr, Pedro Romero, Oezlem Yildiz, Diana Knies, Shao-An Xue
Publikováno v:
Oncotarget, vol. 7, no. 16, pp. 21199-21221
Oncotarget
Oncotarget
Immunotherapy of cancer envisions the adoptive transfer of T-cells genetically engineered with tumor-specific heterodimeric α/β T-cell receptors (TCRα/β). However, potential mispairing of introduced TCRα/β-chains with endogenous β/α-ones may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::553f9a4046c7946242049cbaddf95f14
https://doi.org/10.18632/oncotarget.8385
https://doi.org/10.18632/oncotarget.8385